by Dave Mihalovic

December 12, 2016

from PreventDisease Website
 

The evidence against the use of chemotherapy continues to mount, especially if you're diabetic.

Heart damage caused by chemotherapy is worse in cancer patients with metabolic diseases, according to a study presented EuroEcho-Imaging 2016. The overall contribution of cytotoxic chemotherapy to 5-year survival in adults is well below 3 percent.

Oncologists are now being advised that this toxic treatment has dire consequences for those with metabolic diseases such as diabetes and insulin resistance.

Heart damage is most often related to the total (cumulative) dose of chemotherapy drug given.

"We've always known chemotherapy is damaging to the heart but the level of damage to those with metabolic disease is extensive and the risks may outweigh the benefits," stated oncologist Dr. Maven Rowland commenting on the study.

Cardiac damage can occur even with lower doses of drugs if the person has had previous radiation and specific types of drug therapy.

"Whether it be in the EU, U.S., Russia, Canada, India, Australia among other countries, the treatment is still not advanced enough to spare cardiac muscle cells from damage," concluded Dr. Rowland.

 

"Cardiotoxicity induced by chemotherapy with anthracyclines is being increasingly reported, mainly because a smaller proportion of patients now die from cancer," said lead author Dr Ana Catarina Gomes, a cardiologist in training at the Hospital Garcia de Orta in Almada, Portugal.

 

"In the coming years this cardiotoxicity looks set to increase the burden of heart failure in cancer survivors."

She continued:

"The good news is that cardiotoxicity can be reversible in the early stages before overt heart failure develops. Surveillance programs are hugely beneficial, particularly in the first year of treatment when up to 80% of the systolic dysfunction develops."

Hospital Garcia de Orta has a surveillance program, run by Cardiology, Oncology and Haematology, to monitor cancer patients who receive anthracycline-based chemotherapy.

Clinical and echocardiographic evaluation is conducted before, during and after chemotherapy, regardless of whether or not the patient has symptoms. The aim is to detect cardiotoxicity early so that heart failure can be prevented.

In her research Dr Ana Catarina Gomes investigates factors that could affect the likelihood of patients having heart damage after treatment with anthracyclines. The current study assessed the impact of cardiovascular risk factors and type of cancer on the development of cardiotoxicity to help identify patients at greater risk.

The study included all 83 patients in the surveillance program, of whom 54 had breast cancer, 20 had lymphoma, and nine had gastric cancer.

For each patient, data was collected on demographics, cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidaemia, smoking), previous cardiovascular and non-cardiovascular diseases, and type and cumulative dose of anthracyclines.

Echocardiographic evaluation included heart chamber dimensions, systolic and diastolic function, ejection fraction and global longitudinal strain. Measurements were performed before chemotherapy was started, during treatment, and after the end of chemotherapy.

The researchers tested the impact of each risk factor on changes in echocardiographic data from baseline to follow-up. Echocardiographic data were compared between patients with different types of cancer.

A total of 39 patients were treated with doxorubicin and 44 received epirubicin. Cumulative doses were within recommended ranges. Patients were 52 years old on average (range 39 to 65 years) and 78% were female.

Some,

• 31% had hypertension

• 7% had diabetes

• 16% had dyslipidaemia

• 16% were smokers

Overall, global longitudinal strain and left ventricular ejection fraction progressively decreased and were significantly lower after chemotherapy compared to baseline.

Patients with hypertension showed a trend toward greater reductions in ejection fraction. Patients with diabetes had a significantly greater decrease in global longitudinal strain during treatment, despite having baseline levels similar to non-diabetics.

Dr Gomes said:

"Subclinical reduction in global longitudinal strain is an early predictor of heart failure and was particularly pronounced in patients with diabetes. It is possible that the trend for greater reduction in patients with hypertension might become statistically significant in a larger study."